Point72 Asia (Singapore) Pte. Ltd. Bio Xcel Therapeutics, Inc. Transaction History
Point72 Asia (Singapore) Pte. Ltd.
- $379 Billion
- Q4 2024
A detailed history of Point72 Asia (Singapore) Pte. Ltd. transactions in Bio Xcel Therapeutics, Inc. stock. As of the latest transaction made, Point72 Asia (Singapore) Pte. Ltd. holds 15,939 shares of BTAI stock, worth $53,714. This represents 0.0% of its overall portfolio holdings.
Number of Shares
15,939
Previous 15,186
4.96%
Holding current value
$53,714
Previous $9.26 Million
35.66%
% of portfolio
0.0%
Previous 0.0%
Shares
3 transactions
Others Institutions Holding BTAI
# of Institutions
52Shares Held
8.63MCall Options Held
34.5KPut Options Held
59.4K-
Armistice Capital, LLC New York, NY4.32MShares$14.5 Million0.02% of portfolio
-
Ubs Group Ag1.28MShares$4.3 Million0.0% of portfolio
-
Vanguard Group Inc Valley Forge, PA1.19MShares$4 Million0.0% of portfolio
-
Black Rock Inc. New York, NY441KShares$1.49 Million0.0% of portfolio
-
Geode Capital Management, LLC Boston, MA312KShares$1.05 Million0.0% of portfolio
About BioXcel Therapeutics, Inc.
- Ticker BTAI
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 28,022,500
- Market Cap $94.4M
- Description
- BioXcel Therapeutics, Inc. is a commercial-stage biopharmaceutical company utilizing artificial intelligence approaches to develop transformative medicines in neuroscience and immuno-oncology. The company's drug re-innovation approach leverages existing approved drugs and/or clinically validated product candidates together with big data and prop...